2026 Q2 -tulosraportti
Vain PDF
Tänään
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenI had CHAT GPT evaluate the report and here is the result: Positive: Product revenues increased to 140,0 mill. kroner from 135,6 mill. (+3,2 % reported), despite currency effects. The guidance was raised. Now 8–11 % product growth is expected (previously 7–11 %), while the EBITDA margin is to be improved. The number of active US hospitals increased 20 % to 436, showing that the installed base continues to grow. The FDA process regarding reclassification of BLC equipment appears to proceed in H2 2026. This could be the biggest share price driver over the next 6–18 months. The acquisition of Vesica gives Photocure a new growth leg in urine-based diagnostics, with first revenues expected in 2027 and possible reimbursement already in 2027, otherwise around mid-2028. Slightly weaker: The reported EBITDA was negative due to acquisition costs. Cash holdings fell to 162 millioner kroner, although the company still has a solid balance sheet. Revenue growth in the quarter alone was not spectacular. What do I think the market is reacting to? I believe investors will focus most on: Raised guidance. The FDA catalyst. The Vesica acquisition. Continued growth in installed base. If management on the webcast at 14:00 appears confident that the FDA process is proceeding as planned, it could be more important than the quarterly figures themselves. Cision News Share price after the report If the share was around 56–58 kroner before the report, I would estimate: 40 % probability: 58–62 kroner (moderately positive reaction). 35 % probability: 55–58 kroner (small reaction – the market believes this was roughly as expected). 25 % probability: 63–68 kroner if the webcast gives very positive signals about FDA and Vesica. The rest of 2026 The most important share price drivers are, in my opinion: FDA reclassification of BLC equipment. More installations in the USA. Better utilization of existing hospitals. New biomarker revenues and progress for AssureMDx. Potential partnerships in AI and diagnostics. If these develop positively, I believe Photocure can be valued significantly higher than today. Analyst consensus before the report was 80–90 kroner, with a median target price of 82 kroner. Markit My overall assessment of the report is: Quarterly figures: 7,5/10 Guidance: 9/10 Strategic development: 9,5/10 Overall rating: 8,5/10 I believe this strengthens the case for the next 1–3 years more than it necessarily changes the value over the next couple of trading days. The biggest value driver is still a successful FDA process and faster adoption in the USA.
·3 t sittenPhotocure raises expectations for 2026 today at 08:46 ∙ News overview (AI) Photocure continued to deliver commercial momentum in Q2 2026, driven by a solid performance in the company's core business of bladder cancer diagnostics. The company raised its full-year revenue expectations, reflecting strong market acceptance. Important strategic milestones include the acquisition of Vesica Health to expand the company's diagnostic platform and an upcoming regulatory reclassification from the US FDA. Hexvix/Cysview revenue increased to 140,0 million NOK in Q2 2026 from 135,6 million NOK in Q2 2025. Photocure raised its product revenue growth expectations for 2026 to 8 %–11 % in constant currencies, up from the previous 7 %–11 %. The company acquired Vesica Health and its AssureMDx biomarker test for bladder cancer, with initial revenues expected in 2027. The US FDA plans to initiate the reclassification of blue light cystoscopy (BLC) equipment in H2 2026, which could potentially expand the addressable market. Reported EBITDA fell to -2,0 million NOK compared to 14,8 million NOK in Q2 2025 due to acquisition-related costs of 2,1 million NOK.
·3 t sitten · Muokattuunfortunately it doesn't look like the market is satisfied ??? this is really a tough case, as if it can't get away from down here. With that deficit, I can also understand the investors; time and again they disappoint. Maybe there should be some changes in the management/board; the only thing they do is enrich themselves.
It is now one can potentially make a killing. One can in Q3 : - Get royalty on the first sales of Cevira. - FDA can reclassify - Approval for Cevira in EU. Believe it is a very good time to enter.
·4 t sittenPositive report!! How much will PHO go up?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
Vain PDF
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenI had CHAT GPT evaluate the report and here is the result: Positive: Product revenues increased to 140,0 mill. kroner from 135,6 mill. (+3,2 % reported), despite currency effects. The guidance was raised. Now 8–11 % product growth is expected (previously 7–11 %), while the EBITDA margin is to be improved. The number of active US hospitals increased 20 % to 436, showing that the installed base continues to grow. The FDA process regarding reclassification of BLC equipment appears to proceed in H2 2026. This could be the biggest share price driver over the next 6–18 months. The acquisition of Vesica gives Photocure a new growth leg in urine-based diagnostics, with first revenues expected in 2027 and possible reimbursement already in 2027, otherwise around mid-2028. Slightly weaker: The reported EBITDA was negative due to acquisition costs. Cash holdings fell to 162 millioner kroner, although the company still has a solid balance sheet. Revenue growth in the quarter alone was not spectacular. What do I think the market is reacting to? I believe investors will focus most on: Raised guidance. The FDA catalyst. The Vesica acquisition. Continued growth in installed base. If management on the webcast at 14:00 appears confident that the FDA process is proceeding as planned, it could be more important than the quarterly figures themselves. Cision News Share price after the report If the share was around 56–58 kroner before the report, I would estimate: 40 % probability: 58–62 kroner (moderately positive reaction). 35 % probability: 55–58 kroner (small reaction – the market believes this was roughly as expected). 25 % probability: 63–68 kroner if the webcast gives very positive signals about FDA and Vesica. The rest of 2026 The most important share price drivers are, in my opinion: FDA reclassification of BLC equipment. More installations in the USA. Better utilization of existing hospitals. New biomarker revenues and progress for AssureMDx. Potential partnerships in AI and diagnostics. If these develop positively, I believe Photocure can be valued significantly higher than today. Analyst consensus before the report was 80–90 kroner, with a median target price of 82 kroner. Markit My overall assessment of the report is: Quarterly figures: 7,5/10 Guidance: 9/10 Strategic development: 9,5/10 Overall rating: 8,5/10 I believe this strengthens the case for the next 1–3 years more than it necessarily changes the value over the next couple of trading days. The biggest value driver is still a successful FDA process and faster adoption in the USA.
- ·3 t sittenPhotocure raises expectations for 2026 today at 08:46 ∙ News overview (AI) Photocure continued to deliver commercial momentum in Q2 2026, driven by a solid performance in the company's core business of bladder cancer diagnostics. The company raised its full-year revenue expectations, reflecting strong market acceptance. Important strategic milestones include the acquisition of Vesica Health to expand the company's diagnostic platform and an upcoming regulatory reclassification from the US FDA. Hexvix/Cysview revenue increased to 140,0 million NOK in Q2 2026 from 135,6 million NOK in Q2 2025. Photocure raised its product revenue growth expectations for 2026 to 8 %–11 % in constant currencies, up from the previous 7 %–11 %. The company acquired Vesica Health and its AssureMDx biomarker test for bladder cancer, with initial revenues expected in 2027. The US FDA plans to initiate the reclassification of blue light cystoscopy (BLC) equipment in H2 2026, which could potentially expand the addressable market. Reported EBITDA fell to -2,0 million NOK compared to 14,8 million NOK in Q2 2025 due to acquisition-related costs of 2,1 million NOK.
- ·3 t sitten · Muokattuunfortunately it doesn't look like the market is satisfied ??? this is really a tough case, as if it can't get away from down here. With that deficit, I can also understand the investors; time and again they disappoint. Maybe there should be some changes in the management/board; the only thing they do is enrich themselves.It is now one can potentially make a killing. One can in Q3 : - Get royalty on the first sales of Cevira. - FDA can reclassify - Approval for Cevira in EU. Believe it is a very good time to enter.
- ·4 t sittenPositive report!! How much will PHO go up?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
2026 Q2 -tulosraportti
Vain PDF
Tänään
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenI had CHAT GPT evaluate the report and here is the result: Positive: Product revenues increased to 140,0 mill. kroner from 135,6 mill. (+3,2 % reported), despite currency effects. The guidance was raised. Now 8–11 % product growth is expected (previously 7–11 %), while the EBITDA margin is to be improved. The number of active US hospitals increased 20 % to 436, showing that the installed base continues to grow. The FDA process regarding reclassification of BLC equipment appears to proceed in H2 2026. This could be the biggest share price driver over the next 6–18 months. The acquisition of Vesica gives Photocure a new growth leg in urine-based diagnostics, with first revenues expected in 2027 and possible reimbursement already in 2027, otherwise around mid-2028. Slightly weaker: The reported EBITDA was negative due to acquisition costs. Cash holdings fell to 162 millioner kroner, although the company still has a solid balance sheet. Revenue growth in the quarter alone was not spectacular. What do I think the market is reacting to? I believe investors will focus most on: Raised guidance. The FDA catalyst. The Vesica acquisition. Continued growth in installed base. If management on the webcast at 14:00 appears confident that the FDA process is proceeding as planned, it could be more important than the quarterly figures themselves. Cision News Share price after the report If the share was around 56–58 kroner before the report, I would estimate: 40 % probability: 58–62 kroner (moderately positive reaction). 35 % probability: 55–58 kroner (small reaction – the market believes this was roughly as expected). 25 % probability: 63–68 kroner if the webcast gives very positive signals about FDA and Vesica. The rest of 2026 The most important share price drivers are, in my opinion: FDA reclassification of BLC equipment. More installations in the USA. Better utilization of existing hospitals. New biomarker revenues and progress for AssureMDx. Potential partnerships in AI and diagnostics. If these develop positively, I believe Photocure can be valued significantly higher than today. Analyst consensus before the report was 80–90 kroner, with a median target price of 82 kroner. Markit My overall assessment of the report is: Quarterly figures: 7,5/10 Guidance: 9/10 Strategic development: 9,5/10 Overall rating: 8,5/10 I believe this strengthens the case for the next 1–3 years more than it necessarily changes the value over the next couple of trading days. The biggest value driver is still a successful FDA process and faster adoption in the USA.
- ·3 t sittenPhotocure raises expectations for 2026 today at 08:46 ∙ News overview (AI) Photocure continued to deliver commercial momentum in Q2 2026, driven by a solid performance in the company's core business of bladder cancer diagnostics. The company raised its full-year revenue expectations, reflecting strong market acceptance. Important strategic milestones include the acquisition of Vesica Health to expand the company's diagnostic platform and an upcoming regulatory reclassification from the US FDA. Hexvix/Cysview revenue increased to 140,0 million NOK in Q2 2026 from 135,6 million NOK in Q2 2025. Photocure raised its product revenue growth expectations for 2026 to 8 %–11 % in constant currencies, up from the previous 7 %–11 %. The company acquired Vesica Health and its AssureMDx biomarker test for bladder cancer, with initial revenues expected in 2027. The US FDA plans to initiate the reclassification of blue light cystoscopy (BLC) equipment in H2 2026, which could potentially expand the addressable market. Reported EBITDA fell to -2,0 million NOK compared to 14,8 million NOK in Q2 2025 due to acquisition-related costs of 2,1 million NOK.
- ·3 t sitten · Muokattuunfortunately it doesn't look like the market is satisfied ??? this is really a tough case, as if it can't get away from down here. With that deficit, I can also understand the investors; time and again they disappoint. Maybe there should be some changes in the management/board; the only thing they do is enrich themselves.It is now one can potentially make a killing. One can in Q3 : - Get royalty on the first sales of Cevira. - FDA can reclassify - Approval for Cevira in EU. Believe it is a very good time to enter.
- ·4 t sittenPositive report!! How much will PHO go up?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt